Search Results

He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics

Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics rerouted his path toward a breakthrough GPCR research career The inside story behind founding Blue Therapeutics Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics

Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics They explored the evolution of the field, allosteric modulation concepts, and potential therapeutic approaches Arthur will work on designing ligands for specific receptors, aiming to create biased agonists for therapeutic Yamina discussed the potential of autoantibodies and allosteric modulation in the context of disease and therapeutic endogenous allosteric ligands and the possibility of using a neutral allosteric ligand as a preferred therapeutic

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

particular, drives tumor growth via effects on GBM stem cell self-renewal and metabolism, but also has a therapeutically has been particularly interested in the role adhesion GPCRs play in glioblastoma biology and their therapeutic Javitch1,2 1Departments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University , New York, NY 10032; 2Division of Molecular Therapeutics, New York State Psychiatric Institute, New

Yamina underscores the therapeutic potential of GPR65, especially in the context of cancer immunotherapy , and how understanding receptor activity in acidic microenvironments could unlock new therapeutic strategies

technology for high-throughput screening of pharmacological compound libraries to identify potential therapeutic "Ana Lilia Moreno Salinas (2), Arturo Mancini (1), Raida Jallouli (2), Richard Leduc (2) (1)Domain Therapeutics Laurent Sabbagh on the web Domain Therapeutics Characterizing hADGRE5/CD97 Activation and Signaling: Domain Therapeutics North America Inc., Montreal, Quebec, Canada 3.

From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics years of drug discovery research in the pharmaceutical industry, where he works mainly on GPCRs as therapeutic He is passionate about mechanistic profiling of therapeutic molecules as well as drug discovery in general

protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics

molecular explanation of small molecules for their pre-clinical efficacy and to support the design of novel therapeutics

How target depletion and replenishment kinetics define the therapeutic window.

Saraf " My research focuses on evaluating and targeting serotonin 1A receptors for therapeutic outcomes

Terry Hébert is a Professor within the Department of Pharmacology & Therapeutics at McGill University

the company's ability to predict the residence time of a ligand and its potential correlation with a therapeutic Therapeutic Effect and Receptor Interactions Aurelien Rizk and Yamina had a detailed discussion about the importance of gaining more information about the therapeutic effect in patients or animals and the They also shared their preference for small molecule therapies over protein therapeutics.

This is the kind of advance that matters for anyone building tools, assays, or therapeutics around receptor

of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic

biosensors, cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic

lesson: Target depletion vs. replenishment dynamics — how offset rates control exposure windows, shape therapeutic

One of the best tools to study therapeutic targets are fluorescent ligands, which are very useful in Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic

The result: inconsistent exposure, patchy activity, and sometimes, outright therapeutic failure.

We hope our research will aid in the development of new therapeutic interventions for the alleviation

embody the multifaceted nature of GPCRs, showcasing their complexity, versatility, and potential for therapeutic

Measuring and understanding bias helps design drugs that maximize therapeutic benefits while minimizing See- The Importance of Pharmacologic Assays Lecture 2: Drug Disposition in Physiological Tissues as a Therapeutic Lecture 4: Unconventional GPCR Ligands as Drugs Lecture 5: Unique Exploitable GPCR-Ligand Behaviors for Therapeutic

This is the kind of advance that matters for anyone building tools, assays, or therapeutics around receptor The new blog takes you behind the scenes — the London trip, the early confocal experiments, the pivot translational impact — giving us new ways to think about receptor pharmacology, biased agonism, and therapeutic lesson: Target depletion vs. replenishment dynamics — how offset rates control exposure windows, shape therapeutic The result: inconsistent exposure, patchy activity, and sometimes, outright therapeutic failure.

He is also an Associate Leader of the Experimental Therapeutics and Metabolism Program and the Director

She has advanced the use of computational methods to meet the challenges of designing therapeutics with

Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic

As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery